Kardigan Inc (KARD)

Currency in USD
18.69
-0.99(-5.03%)
Closed·
18.690.00(0.00%)
·
KARD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
18.6920.04
52 wk Range
16.2527.00
Key Statistics
Prev. Close
19.68
Open
19.85
Day's Range
18.69-20.04
52 wk Range
16.25-27
Volume
433.15K
Average Volume (3m)
445.13K
1-Year Change
-
Book Value / Share
6.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KARD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
42.25
Upside
+126.06%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period

Kardigan Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 42.25
(+126.06% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy46.00+146.12%51.00MaintainAug 25, 2026

Earnings

Latest Release
Aug 11, 2026
EPS / Forecast
-4.61 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

KARD Income Statement

Compare KARD to Peers and Sector

Metrics to compare
KARD
Peers
Sector
Relationship
P/E Ratio
−6.1x−4.8x−0.3x
PEG Ratio
-−0.360.00
Price/Book
2.8x0.2x2.6x
Price / LTM Sales
-1.6x3.0x
Upside (Analyst Target)
122.8%52.4%53.8%
Fair Value Upside
Unlock35.0%8.6%Unlock

Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio’s cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
17.21M18.40%338.67M
Other Institutional Investors
88.07M81.60%1.73B
Public Companies & Retail Investors
0.000.00%0.00
Total
105.28M100.00%2.07B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
HRTG GPE, LLC18.09%16,917,034332,927
ARCH Venture Fund XIII, L.P.16.09%15,042,035296,027

People Also Watch

12.19
STDN
-6.52%
34.67
AVLN
-3.37%
39.88
COAG
-10.38%
29.47
SCTX
+0.20%
51.98
ARXS
-0.86%

FAQ

What Is the Kardigan (KARD) Stock Price Today?

The Kardigan stock price today is 18.69 USD.

What Stock Exchange Does Kardigan Trade On?

Kardigan is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Kardigan?

The stock symbol for Kardigan is "KARD."

What Is the Kardigan Market Cap?

As of today, Kardigan market cap is 1.75B USD.

What Is Kardigan's Earnings Per Share (TTM)?

The Kardigan EPS (TTM) is -17.13.

When Is the Next Kardigan Earnings Date?

Kardigan will release its next earnings report on Dec 02, 2026.

From a Technical Analysis Perspective, Is KARD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Kardigan Stock Split?

Kardigan has split 0 times.

What is the current trading status of Kardigan (KARD)?

As of Sep 11, 2026, Kardigan (KARD) is trading at a price of 18.69 USD, with a previous close of 19.68 USD. The stock has fluctuated within a day range of 18.69 USD to 20.04 USD, while its 52-week range spans from 16.25 USD to 27.00 USD.

What Is Kardigan (KARD) Price Target According to Analysts?

The average 12-month price target for Kardigan is 42.25 USD, with a high estimate of 46 USD and a low estimate of 37 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +126.06% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.